Company profile: Adze Biotech
1.1 - Company Overview
Company description
- Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
Products and services
- Adze Oncolytic Immunotherapy Platform: Engineers a chimeric adenoviral backbone enabling systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors for targeted cancer treatment
- Adze-1.17-CD40L: A conditionally replicative oncolytic virus that delivers recombinant human CD40 ligand locally into solid tumors for the treatment of malignant glioma
- Adze-1.17: A tumor-selective oncolytic immunotherapy platform that kills tumor cells and releases tumor-derived antigens to promote a systemic anti-tumor immune response
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adze Biotech
Blue Earth Diagnostics
HQ: United Kingdom
Website
- Description: Provider of molecular PET imaging agents and technologies for cancer diagnosis, developing and commercialising radiopharmaceuticals addressing high unmet medical needs. Offerings include Axumin (fluciclovine F 18) for detecting recurrent prostate cancer, POSLUMA (flotufolastat F 18) Injection for detecting prostate cancer, FAP-targeted PET technology for multiple solid tumors, and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blue Earth Diagnostics company profile →
Theseus Pharmaceuticals
HQ: United States
Website
- Description: Provider of technology-based pharmaceutical offerings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theseus Pharmaceuticals company profile →
NeoGenomics
HQ: United States
Website
- Description: Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeoGenomics company profile →
Mariana Oncology
HQ: United States
Website
- Description: Provider of precision radiopharmaceuticals and radioligand therapeutics for solid tumors, including MC-339 for small cell lung cancer with an actinium-based payload. Offers an integrated discovery and development platform covering target biology, ligand discovery, and optimization, and theranostic approaches using the same ligand for therapy and diagnosis to confirm target engagement, guide patient selection, and optimize dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mariana Oncology company profile →
Janux Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Janux Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adze Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adze Biotech
2.2 - Growth funds investing in similar companies to Adze Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adze Biotech
4.2 - Public trading comparable groups for Adze Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →